Full Press Release Details
Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
PARIS, France, June 4, 2024 Abivax SA (Euronext Paris & Nasdaq: ABVX) ( Abivax or the
Company ), a clinical-stage biotechnology company focused on developing therapeutics that harness the body s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held
its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the General Meeting ), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax
The shareholders have adopted all the resolutions proposed by the Board and, in particular, the financial statements for the
2023 financial year, the compensation policy applicable to the Chairman, the Chief Executive Officer and the directors, as well as delegations granted to the Board related to financial transactions.
The shareholders have also ratified the appointment of Mr. Troy Ignelzi, Dr. June Lee and Ms. Camilla Soenderby as Board members.
Details on the vote results will be available on the Company s website (www.abivax.com).
Obefazimod, Abivax s lead
investigational drug candidate, is an orally administered small molecule that was demonstrated to potentially enhance the expression of a single microRNA, miR-124. Phase 2 clinical trials in patients with UC
have generated positive data, resulting in the initiation of a pivotal global Phase 3 clinical trial program (ABTECT Program), with first patients enrolled in the United States in October 2022. Initiation of a Phase 2b clinical trial in
Crohn s disease is expected in Q3 2024, and exploration of potential combination therapy opportunities in UC is ongoing.
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body s natural regulatory mechanisms to stabilize the
immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active
Abivax Investor Relations
Abivax Communications
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements, forecasts and estimates, including those relating to the
Company s business and financial objectives. Words such as expect, potential, will and variations of such words and similar expressions are intended to identify forward-looking statements. Although
Abivax s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and
uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking
information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorit des March s Financiers pursuant to its legal obligations
including its universal registration document (Document d Enregistrement Universel) and in the Company s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on
April 5, 2024 under the caption Risk Factors. These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by
regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product
candidates. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development including further assessment by the company and regulatory agencies and IRBs/ethics committees following the assessment of
preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are only as of the date of this press release. Readers are cautioned not to place undue reliance
on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information
about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information
contained herein does not constitute either an offer to sell, or the solicitation of an offer to purchase or subscribe securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice.
It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to
change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.